Medical Weight Loss
in Miami

Tirzepatide is a once-weekly injectable medication that activates two gut hormone receptors, GLP-1 and GIP. The dual mechanism reduces appetite, slows gastric emptying, and improves insulin sensitivity. In clinical trials, tirzepatide has produced the largest mean weight reduction of any FDA-approved weight-management medication. It is sold under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for weight loss).

Semaglutide is the active ingredient. Ozempic is the brand approved for type 2 diabetes, Wegovy is the brand approved for weight loss, and Rybelsus is the oral form. All contain the same medication. The TrufaMED program uses FDA-approved semaglutide formulations and licensed compounded semaglutide depending on availability and clinical fit, disclosed transparently before anything is prescribed.

In clinical trials, average total body weight reduction at one year is roughly 15 percent on semaglutide and 20 to 22 percent on the highest dose of tirzepatide. Individual results vary based on starting weight, dose tolerated, adherence, and lifestyle changes. Some patients lose more, some less. A board-certified physician sets realistic expectations during your consultation, based on your labs and history.

GLP-1 medications require physician supervision. Labs before starting, dose titration, side-effect monitoring, and clinical adjustments are not optional. Selling these medications transactionally, without a clinical relationship, is the common model elsewhere, and we believe it produces worse outcomes and higher risk. The concierge structure is how we build in the time and access to do this safely, and it bundles the medication with broader health management.

A CBC, comprehensive metabolic panel, lipid panel, HbA1c, thyroid function (TSH), and lipase, plus a pregnancy test where applicable. Your physician may add further testing based on your history. Baseline labs are included and drawn at our Surfside clinic, most in our own in-house lab.

The most common side effects are gastrointestinal: nausea (especially in the first weeks and after dose increases), reduced appetite (the intended effect), constipation, occasional loose stools, and fatigue during dose-up periods. Most are mild and improve with slow titration. Less common but significant risks include pancreatitis, gallbladder disease, and accelerated gastric emptying. The full risk profile is reviewed during your consultation.

Treatment duration is individualized. Some patients use a GLP-1 for one year of active weight reduction followed by a structured taper or maintenance dose, while others stay on a maintenance dose long-term. When the medication stops, appetite typically returns and some weight regain is common without continued nutrition and behavioral support. Your physician plans your timeline and any taper around your goals, response, and clinical picture.

We dispense both FDA-approved manufacturer formulations and licensed compounded formulations from regulated 503A and 503B pharmacies, depending on availability, clinical appropriateness, and patient preference. Pharmacy sourcing is disclosed before any medication is prescribed. We do not source from unregulated international or unlicensed sellers.

Eligibility is based on BMI thresholds and metabolic risk factors, not a target number of pounds. Most patients in our program have a clinically meaningful goal of fifteen pounds or more, often alongside metabolic syndrome, prediabetes, or related conditions. Patients seeking minor cosmetic weight changes are usually not appropriate candidates, and we will tell you so honestly during the consultation.

Concierge members message the concierge team on WhatsApp at +1 (305) 842-9801. If you are not yet a member, the same conversation is the right place to start, since the program runs inside our concierge practice. The consult reviews your full medical history, current medications, weight goals, and prior attempts, and baseline labs are drawn the same day where appropriate.